Behcets uveitis

被引:82
作者
Tugal-Tutkun, Ilknur [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey
关键词
Behcets Disease; Immunomodulatory Treatment; Retinal Vasculitis; Uveitis;
D O I
10.4103/0974-9233.58425
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Behcets disease is a multisystem inflammatory disorder that is most common in countries along the ancient "Silk Road". The eye is the most commonly involved vital organ in Behets patients and the typical form of involvement is a relapsing remitting panuveitis and retinal vasculitis. Uveitis is the initial manifestation of the disease in 10-15% of the patients. Anterior uveitis is always nongranulomatous. Diffuse vitritis, retinal infiltrates, sheathing of predominantly retinal veins, and occlusive vasculitis are the typical signs of posterior segment inflammation. Spontaneous resolution of acute inflammatory signs is a diagnostic feature. Fundus fluorescein angiography is the gold standard in monitoring inflammatory activity. Laser flare photometry is a useful noninvasive tool since flare readings correlate with fluorescein angiographic leakage. The most common complications are cataract, maculopathy, and optic atrophy. Male patients have a more severe disease course and worse visual prognosis. Immunomodulatory therapy is indicated in all patients with posterior segment involvement. Corticosteroids combined with azathioprine and/or cyclosporine is used initially. Biologic agents, including interferon alfa and infliximab, are used in resistant cases. Visual prognosis has improved in recent years with an earlier and more aggressive use of immunomodulatory therapy and the use of biologic agents in resistant cases.
引用
收藏
页码:219 / 224
页数:6
相关论文
共 53 条
[1]   Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease [J].
Abu El-Asrar A.M. ;
Abboud E.B. ;
Aldibhi H. ;
Al-Arfaj A. .
International Ophthalmology, 2005, 26 (3) :83-92
[2]   Clinical patterns of neurological involvement in Behcet's disease:: evaluation of 200 patients [J].
Akman-Demir, G ;
Serdaroglu, P ;
Tasçi, B .
BRAIN, 1999, 122 :2171-2181
[3]  
[Anonymous], 1992, Br J Rheumatol, V31, P299
[4]   Prevalence of Behcet's disease in Istanbul, Turkey [J].
Azizlerli, G ;
Köse, AA ;
Sarica, R ;
Gül, A ;
Tutkun, IT ;
Kulaç, M ;
Tunç, R ;
Urgancioglu, M ;
Disçi, R .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2003, 42 (10) :803-806
[5]  
Behcet H, 1937, DERMATOL WOCHENSCHR, V105, P1152
[6]   Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey [J].
Demiroglu, H ;
Barista, I ;
Dundar, S .
OPHTHALMOLOGY, 1997, 104 (04) :701-705
[7]   Autoimmunity vs autoinflammation in Behcet's disease:: do we oversimplify a complex disorder? [J].
Direskeneli, H. .
RHEUMATOLOGY, 2006, 45 (12) :1461-1465
[8]   Current concepts in the etiology and treatment of Behcet disease [J].
Evereklioglu, C .
SURVEY OF OPHTHALMOLOGY, 2005, 50 (04) :297-350
[9]   Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behcet's disease [J].
Gedik, S ;
Akova, YA ;
Yilmaz, G ;
Bozbeyoglu, S .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2005, 13 (01) :51-58
[10]   Long-term Efficacy and Safety of Low-dose Interferon Alpha2a Therapy in Severe Uveitis Associated With Behcet Disease [J].
Gueudry, Julie ;
Wechsler, Bertrand ;
Terrada, Celine ;
Gendron, Gael ;
Cassoux, Nathalie ;
Fardeau, Christine ;
Lehoang, Phuc ;
Piette, Jean-Charles ;
Bodaghi, Bahram .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 146 (06) :837-844